David A. Siegel Genfit S.A. Transaction History

Two Sigma Advisers, LP

  • $43.8 Billion
  • Q2 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022
SELL
$3.26 - $4.86 $4,564 - $6,804
-1,400 Reduced 10.37%
12,100 $44,000
Q2 2022

Aug 15, 2022
SELL
$3.09 - $4.25 $77,868 - $107,100
-25,200 Reduced 65.12%
13,500 $43,000
Q1 2022

May 16, 2022
BUY
$3.14 - $5.04 $121,518 - $195,048
38,700 New
38,700 $155,000

Others Institutions Holding GNFT

# of Institutions
8
Shares Held
49.2K
Call Options Held
0
Put Options Held
0
View Full List

About Genfit S.A.

GNFT Quotes by TradingView
  • Ticker GNFT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,815,500
  • Market Cap $264M
  • Description
  • Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagno...
More about GNFT
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email